Manish Kohli

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Characterization of human plasma-derived exosomal RNAs by deep sequencing
    Xiaoyi Huang
    Department of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    BMC Genomics 14:319. 2013
  2. pmc Germline predictors of androgen deprivation therapy response in advanced prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 87:240-6. 2012
  3. doi request reprint Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Cancer Biomark 7:101-8. 2010
  4. pmc Thrombin expression in prostate: a novel finding
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Invest 29:62-7. 2011
  5. pmc Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells
    Saswati Mahapatra
    Department of Urology, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Evid Based Complement Alternat Med 2012:303019. 2012
  6. pmc Androgen deprivation therapy-associated vasomotor symptoms
    Jason M Jones
    Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Asian J Androl 14:193-7. 2012
  7. pmc The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort
    Mohammed Nabhan
    Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:540-7. 2012
  8. pmc Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer
    Saswati Mahapatra
    Department of Urology and Biochemistry Molecular Biology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    AAPS J 13:365-77. 2011
  9. pmc Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Adv Urol 2012:781459. 2012
  10. pmc New developments in the medical management of prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:77-86. 2010

Collaborators

Detail Information

Publications10

  1. pmc Characterization of human plasma-derived exosomal RNAs by deep sequencing
    Xiaoyi Huang
    Department of Pathology and Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    BMC Genomics 14:319. 2013
    ..In all we evaluated 14 libraries (7 replicates)...
  2. pmc Germline predictors of androgen deprivation therapy response in advanced prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 87:240-6. 2012
    ....
  3. doi request reprint Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Cancer Biomark 7:101-8. 2010
    ..An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer...
  4. pmc Thrombin expression in prostate: a novel finding
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Invest 29:62-7. 2011
    ..A variable repertoire of coagulation protein expression is observed in different cancers. We evaluated expression of thrombin in prostate tissue...
  5. pmc Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells
    Saswati Mahapatra
    Department of Urology, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Evid Based Complement Alternat Med 2012:303019. 2012
    ..EENL treatment could have a potential therapeutic role during cancer progression...
  6. pmc Androgen deprivation therapy-associated vasomotor symptoms
    Jason M Jones
    Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Asian J Androl 14:193-7. 2012
    ..This article reviews current options for the treatment of hot flashes in patients taking ADT...
  7. pmc The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort
    Mohammed Nabhan
    Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:540-7. 2012
    ..To determine whether higher intensity of prostate-specific antigen (PSA) surveillance was associated with earlier detection of biochemical recurrence (BCR) or survival...
  8. pmc Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer
    Saswati Mahapatra
    Department of Urology and Biochemistry Molecular Biology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    AAPS J 13:365-77. 2011
    ....
  9. pmc Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Adv Urol 2012:781459. 2012
    ....
  10. pmc New developments in the medical management of prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:77-86. 2010
    ..Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer...